Navigation Links
Pixel Bridge Works With Anika Therapeutics to Launch New Website
Date:8/20/2008

Pixel Bridge, a Boston-based interactive marketing and Web development firm recently announced the launch of a new website for Anika Therapeutics - www.anikatherapeutics.com. Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing joint health, aesthetic, ophthalmic, veterinary and anti-adhesion markets. The company worked with Pixel Bridge to plan, design, develop and implement the new site.

Boston, MA (PRWEB) August 20, 2008 -- Pixel Bridge, a Boston-based interactive marketing and Web development firm recently announced the launch of a new website for Anika Therapeutics - www.anikatherapeutics.com. Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing joint health, aesthetic, ophthalmic, veterinary and anti-adhesion markets. The company worked with Pixel Bridge to plan, design, develop and implement the new site.

For more than 20 years, Anika has been a leader in developing therapies that leverage the benefits of hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body that enhances joint function and coats, protects, cushions and lubricates soft tissues. The company is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

The company's new interactive property is version 2.0 of the site. The key underlying goals associated with the project were to:

  • Effectively educate site visitors about the company's products

  • Visually represent Anika as an innovative leader in its markets

  • Clearly articulate the company's value proposition and market differentiation

"Our goal in designing this site was to capture the energy and entrepreneurial spirit of the company, along with its long history of leadership in therapeutic technologies," said Scott Stephens, president of Pixel Bridge. "Anika has a broad range of therapies in the market and an impressive pipeline of innovative products under development. This demanded a site that was both comprehensive and easy to navigate and reflective of the company's vision for the future. The new website illustrates the company's uniqueness and we were proud to work with them on the project."

"Pixel Bridge worked with us on every step of this engagement - from concept to completion," notes Kevin Quinlan, CFO and Treasurer at Anika. "The firm's full range of capabilities made a potentially cumbersome project streamlined and relatively painless."

ABOUT ANIKA THERAPEUTICS
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products include ORTHOVISC(R), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS(TM) family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation marketed in the U.S. by Artes Medical, Inc.; AMVISC(R), AMVISC(R) Plus, STAARVISC(TM)-II and Shellgel(TM) injectable viscoelastic HA products for ophthalmic surgery; INCERT(R), an HA-based anti-adhesive for surgical applications; ORTHOVISC(R) mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC(TM) a single-injection osteoarthritis product based on our proprietary cross-linking technology and also available in Europe; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA. For more information contact Anika at 781-457-9000 or visit www.anikatherapeutics.com.

ABOUT PIXEL BRIDGE
Pixel Bridge is a Boston-based interactive marketing and Web development firm that helps clients use the Internet to improve marketing, sales, and operations. Founded in 1999, the company seamlessly blends strategy, marketing, creative, and technology expertise to deliver highly effective websites, interactive marketing programs, and custom Internet applications. Pixel Bridge's client roster includes leading Boston-based companies such as The Boston Globe, Constant Contact, and Mac-Gray Corporation, as well as internationally recognized brands including Comcast, ITW, Krups, and Thomson. For more information contact Pixel Bridge at 617-542-5587 or visit www.pixelbridge.com.

Contacts
Pixel Bridge
Erin LaSpina
Tel: 617-542-5587
elaspina @ pixelbridge.com

2008 Pixel Bridge Inc, All Rights Reserved

###

Read the full story at http://www.prweb.com/releases/anikatherapeutics/newwebsite/prweb1226734.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
2. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
3. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
7. NIST team proves bridge from conventional to molecular electronics possible
8. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
9. Woodbridge Offers the Broadest Range of BioFoam(TM) Green Polyurethane Automotive Interior Applications
10. Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... Calif. , March 22, 2017  UBM ... proud to announce their extended partnership and the ... be headlined by the 21 st Annual ... Boston, taking place May 3-4, 2017. ... Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced ... of their live events series, “Stem Cell Therapy: The Next Phase in the Evolution ... 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission to ...
Breaking Biology Technology:
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):